Embla Medical (EMBLA) Investor presentation summary

Key milestones and strategic initiatives

• Achieved majority investment in Streifeneder ortho.production and continued global rebranding of Patient Care facilities to ForMotion, including expansion in Australia and the US.

• Launched new bionic knee products (Icon, Navii) and Odyssey iQ, and received a new US reimbursement code for NEURO HITRONIC MPKAFO.

• Named to Forbes Accessibility 100 and recognized by TIME Magazine for sustainable growth for the second consecutive year.

• Expanded support for Ukrainian amputees with a new clinic in Kyiv and partnership in Iceland.

• Appointed new EVPs for Patient Care and R&D to strengthen leadership.

Financial performance and outlook

• FY 2025 reported sales growth of 9% (6% organic), with EBITDA margin at 20%; Q4 reported growth was 14% (7% organic), EBITDA margin at 19%.

• EMEA and APAC regions delivered strong Q4 growth (12% and 9% organic, respectively), while Americas remained flat.

• Prosthetics & Neuro Orthotics saw 10% organic growth in FY 2025, while Bracing & Supports declined by 1% and Patient Care grew 1%.

• Net profit increased 33% in Q4 and 21% for FY 2025; EBITDA grew 10% for the year.

• 2026 guidance: organic sales growth of 5-8% and EBITDA margin of 20-22% before special items.

Business segments and market dynamics

• Prosthetics & Neuro Orthotics accounted for 51% of sales, Patient Care 33%, and Bracing & Supports 16%.

• Only 30-40% of new leg amputees globally are fitted with prosthetics, with emerging markets representing 80% of new amputee volume but only 10% of current sales.

• Bionics sales represent over 25% of prosthetics revenue, with strong recurring sales and innovation driving growth.

• Neuro Orthotics is an attractive, high-growth segment with low penetration outside Germany and significant long-term potential.

• Bracing & Supports faces competitive pressure and price sensitivity, but growth initiatives and new launches are expected to drive recovery.